Updated population pharmacokinetic (popPK) model for emapalumab using data from four prospective clinical trials in patients with hemophagocytic lymphohistiocytosis/macrophage activation syndrome (MAS)

• EHA •
• 11 June, 2026 •
• •

Emapalumab in Treatment-Experienced Primary HLH: Safety, Efficacy, and Transplant Outcomes from the Open-Label, Single-Arm Post-Authorization Study Sobi.EMAPALUMAB-104 in Chinese Patients

Rui Zhang, Xiaowen Zhai, Andrew Danquah, Ben Peace, Per Hedlund, Andrew Ramsey, Rafael Krmar, Brian Jamieson

• CCR East •
• 1 May, 2026 •
• •

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)

Alexei A. Grom, Shoghik Akoghlanian, Melissa Elder, Renee Modica, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

Available materials

• CCR East •
• 1 May, 2026 •
• •

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Edward M. Behrens, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullman, Adnan Mahmood, Andrew Danquah, Elena Burillo, Steve Mallett, Brian D. Jamieson, Alexei A. Grom, Fabrizio De Benedetti

Available materials

• CCR East •
• 1 May, 2026 •
• •

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Alexei A. Grom, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Edward M. Behrens, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullman, Adnan Mahmood, Andrew Danquah, Elena Burillo, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

Available materials